Diagnosis and Management of Portal Vein Thrombosis in Liver Cirrhosis
DOI:
https://doi.org/10.24871/261202568-75Keywords:
Cirrhosis, portal vein thrombosis, anticoagulantAbstract
Portal vein thrombosis is formation of thrombus in main portal vein and its branches, that may also affect superior or mesenteric veins. Rebalanced coagulation system and changes in hepatic portal venous flow augment risk of portal vein thrombosis. Modalities to identify portal vein thrombosis include ultrasonography, contrast enhanced Computed Tomography (CT), and Magnetic Resonance Imaging (MRI). The management of portal vein thrombosis in hepatic cirrhosis is challenging due to intricate balance between thrombosis and bleeding complicating treatment decision. Treatment option consisted of close monitoring, anticoagulation, thrombolysis, and trans-jugular intrahepatic portosystemic shunt (TIPS). Anticoagulant options for management of portal vein thrombosis encompass Low Molecular Weight Heparin (LMWH), Vitamin K Antagonist (VKA), and Direct Oral Anticoagulant (DOAC). There is still no consensus regarding the thrombolysis for the management of portal vein thrombosis in cirrhosis due to lack of evidence. TIPS may be considered in portal vein thrombosis with insufficient response or contraindication to anticoagulation, repeated variceal bleeding, and/ or refractory ascites which unable to be controlled by medical or endoscopic management. This review aims to discuss the current update in diagnosis and management of portal vein thrombosis in liver cirrhosis.Keywords: Cirrhosis, portal vein thrombosis, anticoagulantReferences
Shukla A, Giri S. Portal Vein Thrombosis in Cirrhosis. J Clin Exp Hepatol. 2022;12(3):965-79.
Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. Gastroenterology. 2019;156(6):1582-99.
Wu M, Schuster M, Tadros M. Update on Management of Portal Vein Thrombosis and the Role of Novel Anticoagulants. J Clin Transl Hepatol. 2019;7(2):154-64.
Zhang Y, Xu B-y, Wang X-b, et al. Prevalence and Clinical Significance of Portal Vein Thrombosis in Patients With Cirrhosis and Acute Decompensation. Clin Gastroenterol Hepatol. 2020;18(11):2564-72.
Pan J, Wang L, Gao F, et al. Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis. Eur J Intern Med. 2022;104:21-32.
Noronha Ferreira C, Marinho RT, Cortez-Pinto H, et al. Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: A prospective study. Liver Int. 2019;39(8):1459-67.
Nicoară-Farcău O, Soy G, Magaz M, et al. New Insights into the Pathogenesis, Risk Factors, and Treatment of Portal Vein Thrombosis in Patients with Cirrhosis. Semin Thromb Hemost. 2020;46(06):673-81.
Anton A, Campreciós G, Pérez-Campuzano V, et al. The Pathophysiology of Portal Vein Thrombosis in Cirrhosis: Getting Deeper into Virchow's Triad. J Clin Med. 2022;11(3).
Xu S, Guo X, Yang B, et al. Evolution of Nonmalignant Portal Vein Thrombosis in Liver Cirrhosis: A Pictorial Review. Clin Transl Gastroenterol. 2021(10):1-8.
Rugivarodom M, Charatcharoenwitthaya P. Nontumoral Portal Vein Thrombosis: A Challenging Consequence of Liver Cirrhosis. J Clin Transl Hepatol. 2020;8(4):432-44.
Sarin SK, Philips CA, Kamath PS, et al. Toward a Comprehensive New Classification of Portal Vein Thrombosis in Patients With Cirrhosis. Gastroenterology. 2016;151(4):574-7.
De Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII – Renewing consensus in portal hypertension. Journal of Hepatology. 2022;76(4):959-74.
Hepatobiliary Disease Study Group Chinese Society of Gastroenterology Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai). J Dig Dis. 2021;22(4):176-86.
Senzolo M, Garcia-Tsao G, GarcÃa-Pagán JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol. 2021;75(2):442-53.
Guerrero A, Campo Ld, Piscaglia F, et al. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis. J Hepatol. 2023;79(1):69-78.
Ferreira CN, Reis D, Cortez-Pinto H, et al. Anticoagulation in Cirrhosis and Portal Vein Thrombosis Is Safe and Improves Prognosis in Advanced Cirrhosis. Dig Dis Sci. 2019;64(9):2671-83.
Wang L, Guo X, Xu X, et al. Anticoagulation Favors Thrombus Recanalization and Survival in Patients With Liver Cirrhosis and Portal Vein Thrombosis: Results of a Meta-Analysis. Adv Ther. 2021;38(1):495-520.
Niu C, Zhang J, Himal K, et al. Impact of anticoagulation therapy on outcomes in patients with cirrhosis and portal vein thrombosis: A large-scale retrospective cohort study. Thromb Res. 2024;241:1-6.
Odriozola A, Puente Ã, Cuadrado A, et al. Portal Vein Thrombosis in the Setting of Cirrhosis: A Comprehensive Review. J Clin Med. 2022;11(21):1-26.
Chun HS, Choe AR, Lee M, et al. Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis. Clin Mol Hepatol. 2021;27(4):535-52.
Ai M-H, Dong W-G, Tan X-P, et al. Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2020;32(10):1395-400.
Nagaoki Y, Aikata H, Daijyo K, et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res. 2018;48(1):51-8.
Ng CH, Tan DJH, Nistala KRY, et al. A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis. Hepatol Int. 2021;15(5):1196-206.
Koh JH, Liew ZH, Ng GK, et al. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis. Dig Liver Dis. 2022;54(1):56-62.
Zhou H, Wu M, Yu S, et al. Comparison of the efficacy and safety between rivaroxaban and dabigatran in the treatment of acute portal vein thrombosis in cirrhosis. BMC gastroenterol. 2023;23(1):1-9.
Pereira Portela C, Gautier LA, Zermatten MG, et al. Direct oral anticoagulants in cirrhosis: Rationale and current evidence. JHEP Rep. 2024;6(8):101116.
De Santis A, Moscatelli R, Catalano C, et al. Systemic thrombolysis of portal vein thrombosis in cirrhotic patients: A pilot study. Dig Liver Dis. 2010;42(6):451-5.
Primignani M, Tosetti G, Ierardi AM. Approach to different thrombolysis techniques and timing of thrombolysis in the management of portal vein thrombosis in cirrhotic patients. J Transl Med. 2023;11(3):198-202.
Rodrigues SG, Sixt S, Abraldes JG, et al. Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Aliment Pharmacol Ther. 2019;49(1):20-30.
Zhang Z, Zhao Y, Han B, et al. The Efficacy and Safety of Anticoagulants in the Treatment of Cirrhotic Portal Vein Thrombosis: A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost. 2022;28:1-10.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).